S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Major Financial Crisis Could Hit America (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Major Financial Crisis Could Hit America (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Major Financial Crisis Could Hit America (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Major Financial Crisis Could Hit America (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Major Financial Crisis Could Hit America (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Major Financial Crisis Could Hit America (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Major Financial Crisis Could Hit America (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Major Financial Crisis Could Hit America (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?

Altimmune (ALT) Stock Forecast, Price & News

$4.04
+0.04 (+1.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$3.98
$4.16
50-Day Range
$3.87
$5.97
52-Week Range
$3.82
$23.49
Volume
2.16 million shs
Average Volume
1.78 million shs
Market Capitalization
$199.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.14

Altimmune MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
547.1% Upside
$26.14 Price Target
Short Interest
Bearish
17.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$80,630 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.77) to ($2.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

610th out of 1,006 stocks

Pharmaceutical Preparations Industry

302nd out of 492 stocks


ALT stock logo

About Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Receive ALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

ALT Stock News Headlines

"How war impacts the stock market"
Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your Retirement
Altimmune: Q1 Earnings Insights
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
7 Analysts Have This to Say About Altimmune
Altimmune, Inc. (NASDAQ:ALT) Short Interest Up 16.0% in March
See More Headlines
Receive ALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

ALT Company Calendar

Last Earnings
5/11/2023
Today
5/31/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALT
Employees
47
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.14
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+547.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-84,710,000.00
Net Margins
-2,618.74%
Pretax Margin
-2,624.67%

Debt

Sales & Book Value

Annual Sales
$4.41 million
Book Value
$3.40 per share

Miscellaneous

Free Float
47,720,000
Market Cap
$199.13 million
Optionable
Optionable
Beta
-0.08

Key Executives

  • Vipin K. Garg
    President, Chief Executive Officer & Director
  • Richard I. Eisenstadt
    Secretary, Chief Financial & Accounting Officer
  • M. Scot Roberts
    Chief Scientific Officer
  • Bertrand Georges
    Chief Technology Officer
  • M. Scott Harris
    Chief Medical Officer













ALT Stock - Frequently Asked Questions

Should I buy or sell Altimmune stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALT shares.
View ALT analyst ratings
or view top-rated stocks.

What is Altimmune's stock price forecast for 2023?

7 Wall Street research analysts have issued 1 year price targets for Altimmune's stock. Their ALT share price forecasts range from $6.00 to $50.00. On average, they predict the company's stock price to reach $26.14 in the next twelve months. This suggests a possible upside of 547.1% from the stock's current price.
View analysts price targets for ALT
or view top-rated stocks among Wall Street analysts.

How have ALT shares performed in 2023?

Altimmune's stock was trading at $16.45 on January 1st, 2023. Since then, ALT stock has decreased by 75.4% and is now trading at $4.04.
View the best growth stocks for 2023 here
.

When is Altimmune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ALT earnings forecast
.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. The firm had revenue of $0.02 million for the quarter. Altimmune had a negative trailing twelve-month return on equity of 45.37% and a negative net margin of 2,618.74%.

When did Altimmune's stock split?

Shares of Altimmune reverse split on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Altimmune own?
What is Altimmune's stock symbol?

Altimmune trades on the NASDAQ under the ticker symbol "ALT."

Who are Altimmune's major shareholders?

Altimmune's stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (10.06%), Ardsley Advisory Partners LP (2.94%), BlackRock Inc. (2.83%), Two Sigma Investments LP (2.12%), Two Sigma Advisers LP (1.93%) and Dimensional Fund Advisors LP (1.15%). Insiders that own company stock include David Drutz, Diane Jorkasky, Klaus Schafer, M Scot Roberts, Matthew Scott Harris, Philip Hodges, Venrock Healthcare Capital Par, Vipin K Garg and Wayne Pisano.
View institutional ownership trends
.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $4.04.

How much money does Altimmune make?

Altimmune (NASDAQ:ALT) has a market capitalization of $199.13 million and generates $4.41 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.

How can I contact Altimmune?

Altimmune's mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The official website for the company is altimmune.com. The company can be reached via phone at (240) 654-1450, via email at arr@lifesciadvisors.com, or via fax at 410-269-2601.

This page (NASDAQ:ALT) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -